Compare Royal Caribbean Cruises Ltd (RCL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Repligen Corporation Common Stock — how do they compare? Royal Caribbean Cruises Ltd trades at $275 (market cap $75.29B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 6.8× Repligen Corporation Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Repligen Corporation Common Stock for 0 Days on average.
| RCL | RGEN | |
|---|---|---|
Market Cap | $75.29B | $11.14B |
Volume | 1,401,290 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $194.57 |
52-Week Low | $230.30 | $102.87 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $97.93B | $11.02B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.51, up 0.3% with a bullish technical signal. The company shows strong fundamental momentum with Q1 and Q2 2026 earnings beats, robust profitability (23.5% net margin), and improving cash flow. Recent news highlights a $3 billion Sandals Resorts acquisition expanding into the resort market. Technical indicators show the stock trading near pivot point resistance at $285 with strong support at $276.
RCL presents a compelling growth story with accelerating revenue and earnings, though faces execution risks from the Sandals integration and fuel cost pressures. Analyst consensus remains bullish with a $344 price target representing 22% upside potential. The stock's premium valuation (P/E 17.4) appears justified by strong ROE (45.3%) and consistent earnings outperformance.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
